Another emerging target is the hepatocyte growth factor receptor c-Met, which has been implicated in metastatic progression and trastuzumab resistance, and CAR-T-cell designs targeting c-Met + breast cancer models have demonstrated activity [61]. Here, MET is linked to breast carcinoma.